Does Wellbutrin 150 work? (+3 Factors)
By
Dr Milena Locci de Oliveira (PhD)
Author bio
Dr Milena Locci de Oliveira is a Pharmacist and Doctor of Philosophy in Sciences from the University of São Paulo (USP). She has experience in microbiology, analytical toxicology, and clinical pharmacokinetics. She writes and reviews content on these topics.
Dr Milena’s Highlights:
-PhD in Sciences, University of São Paulo, Brazil, 2019.
-University College London (UCL) – Semester of remote collaboration in the areas of Pharmacometrics and Population Pharmacokinetics, 2018.
-Bachelor in Biochemical Pharmacy, University of São Paulo, Brazil, 2013.
“Science can be translated, and it is essential that everyone has access to quality information to make informed decisions” – Dr Milena Oliveira, PhD.
Professional Experience:
With a decade-long career as a researcher, Dr Milena has amassed extensive experience in conducting research projects in microbiology, analytical toxicology, and clinical pharmacokinetics.
Her expertise also extends to the preparation of technical and scientific reports, literature reviews, data analysis, and scientific communication, both oral and written.
Dr Milena has served as a Clinical Pharmacist, providing expert supervision and guidance to teams during the challenging times of the COVID-19 pandemic, particularly in the ICUs of two reference hospitals for patient hospitalization.
In her most recent role, Dr Milena worked on the implementation of the deliberatives of the São Paulo State Government Pharmaceutical Assistance Coordination. These decisions were aimed at ensuring medication access within the Unified Health System.
A widely multidisciplinary background enabled Dr Milena to become a professional capable of integrating scientific knowledge into private initiatives, education, and healthcare, delivering consistent services in patient safety and population health.
Professional Memberships & Affiliations:
Dr Milena Oliveira is a member of the Regional Council of Pharmacy of the State of São Paulo, Brazil.
Education:
-PhD in Sciences, University of São Paulo, Brazil, 2019.
-University College London (UCL) – Semester of remote collaboration, 2018.
-Bachelor in Biochemical Pharmacy, University of São Paulo, Brazil, 2013.
Relevant Published Work & Citations:
Oliveira ML de, Rocha A, Nardotto GHB, Pippa LF, Simões BP, Lanchote VL. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia. Journal of Pharmaceutical and Biomedical Analysis. Nov 2020. 191:113-124.
Abstracts. CPT: Pharmacometrics & Systems Pharmacology. 2020 Nov; 9 (S1).
Pippa LF, Oliveira ML de, Rocha A, de Andrade JM, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis. 2020 Jun 5; 185:113-231.
Godoy ALPC, De Jesus C, De Oliveira ML, Rocha A, Pereira MPM, Larangeira DF, Lanchote VL, Barrouin-Melo SM. Determination of Allopurinol and Oxypurinol in Dogs Plasma by High-Performance Liquid Chromatography with an Ultraviolet Detector: Application for Pharmacokinetic Studies. J Chromatogr Sep Tech. 2017; 8 (4).
Clímaco EC, Oliveira ML de, Pitondo-Silva A, Oliveira MG, Medeiros M, Lincopan N, et al. Clonal complexes 104, 109 and 113 playing a major role in the dissemination of OXA-carbapenemase-producing Acinetobacter baumannii in Southeast Brazil. Infection, Genetics and Evolution. 2013 Oct;19:127–33.
Conference Papers:
Oliveira, M. L.; NARDOTTO, G. H. B.; PIPPA, L. F.; ROCHA, A.; SIMOES, B. P.; LANCHOTE, V. L. . Daunorubicin metabolism and urinary excretion in patients with acute myeloid leukemia. In: 84th Annual Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) and the 20th Annual Meeting of the Association of the Clinical Pharmacology Germany (VKliPha), 2018, Göttingen. Naunyn-Schmiedeberg’s Arch Pharmacol, 2018. v. 391. p. S76-S76.
Oliveira, M. L.; NARDOTTO, G. H. B. ; ROCHA, A. ; SIMOES, B. P. ; LANCHOTE, V. L. . The low contribution of urinary excretion in the elimination of daunorubicin and its metabolite daunorubicinol in patients with acute myeloid leukemia. In: 49th Brazilian Congress of Pharmacology and Experimental Therapeutics., 2017, Ribeirão Preto. Livro de Resumos, 2017. p. 64-64.
Oliveira, M. L.; PIPPA, L. F. ; ROCHA, A. ; SIMOES, B. P. ; LANCHOTE, V. L. . Quantification of daunorubicin and its metabolite daunorubicinol in human plasma by LC-MS/MS. In: I International Meeting of Environmental Health and Toxicology (IMEHTOX), 2016, Ribeirão Preto. Livro de Resumos, 2016.
Oliveira, M. L.; Clímaco, E.C. ; OLIVEIRA, M. G. ; Lincopan, N. ; Darini A.L.C. . PFGE typing of Carbapenem-Resistant Acinetobacter baumannii isolated from different University Hospitals. In: V International Postgraduate and Research Symposium, 2012.
Clímaco, E.C. ; SILVA, A. P. ; Oliveira, M. L. ; OLIVEIRA, M. G. ; Lincopan, N. ; Darini A.L.C. Relação clonal entre linhagens de Acinetobacter baumannii produtoras de carbapenemases da família OXA em quatro hospitais no Brasil. In: XXI Latin American Congress of Microbiology, 2012, Santos. XXI Latin American Congress of Microbiology, 2012.
Oliveira, M. L.; Clímaco, E.C. ; OLIVEIRA, M. G. ; Darini A.L.C. . Dissemintion of OXA carbapenemases genes in carbapenem-resistant Acinetobacter baumannii in University Hospital of Juiz de Fora, MG. In: 8th CIFARP – International Congress of Pharmaceutical Sciences, 2011, Ribeirão Preto.
Clímaco, E.C. ; Oliveira, M. L. ; OLIVEIRA, M. G. ; Darini A.L.C. . Avaliação do sequenciamento parcial do gene rpoB e de seus flanqueadores para identificação de espécies de Acinetobacter na rotina laroratorial. In: 2° International Symposium on Clinical Microbiology, 2010, Florianópolis.
You can view some of Dr Milena’s work below and links to her professional profile.
Linkedin: https://www.linkedin.com/in/dra-milena-locci-de-oliveira-28986042/?locale=en_US
ResearchGate: https://www.researchgate.net/profile/Milena-Oliveira-6
Escavador: https://www.escavador.com/sobre/5394254/milena-locci-de-oliveira
Lattes: https://buscatextual.cnpq.br/buscatextual/busca.do
Scopus: https://www.scopus.com/authid/detail.uri?authorId=57199779361
Scholar: https://scholar.google.com/citations?view_op=list_works&hl=pt-BR&user=1YUBDIQAAAAJ
In this article, we will discuss the working effectiveness of Wellbutrin 150mg, the factors affecting its performance, the common side effects and compare it with other antidepressants like SSRIs.
Does Wellbutrin 150 work?
Yes, Wellbutrin 150 mg may work for some individuals in treating depression and may also help with smoking cessation. However, its effectiveness varies from person to person, and it may not work for everyone. It’s essential to consult with a healthcare professional for personalized guidance and treatment recommendations.
What is the intended Purpose of Wellbutrin 150 mg?
Wellbutrin 150 mg is a medication primarily prescribed to treat major depressive disorder (MDD). It is also utilized to aid in smoking cessation by reducing nicotine cravings. The active ingredient in Wellbutrin 150 mg is Burropion which belongs to a class of atypical antidepressants.
The Wellbutrin 150mg dosage is a common starting point for many patients, and healthcare providers may adjust it based on an individual’s response and tolerance.
What influences Wellbutrin 150 mg’s working? (+3 factors)
The working of Wellbutrin 150mg can be influenced by several factors:
Dosage
The prescribed dosage can impact its effectiveness. It is generally prescribed at a standard dosage of 150mg per day. Healthcare professionals often start from this dose to assess the response of the patient (1).
People may respond differently to the same dose due to factors like their body weight, metabolism, and the severity of their condition. Some patients experience significant improvements with a standard 150mg dose, while others may require adjustments.
If the initial dosage proves insufficient in alleviating the symptoms, the doctors prefer to increase the dose. This can involve taking 300mg per day (2 tablets of 150mg).
Treatment Duration
Wellbutrin 150mg, like many antidepressant medications, may not provide immediate relief. It typically takes several weeks of consistent use before patients experience the complete benefit of the medication (2).
The duration of treatment can vary depending on individual response and the nature of their condition. In cases of depression, doctors often recommend continuing the medication for several months and sometimes longer to maintain symptom relief and reduce the risk of relapse.
Co-existing Medical Conditions
Some co-existing medical conditions like seizures, eating disorders, and liver or kidney disease may interact with Wellbutrin 150mg, influencing its effectiveness.
What are Wellbutrin 150mg common side effects?
Common side effects of Wellbutrin 150mg may include (3):
- Insomnia
- Heartburn
- Dry Mouth
- Headache
- Nausea or Vomiting
- Weight loss
- Agitation or Restlessness
It is important to know that these symptoms may vary from person to person. Always consult a doctor on managing the side effects of any medicine.
Who should not take Wellbutrin 150mg?
You shouldn’t use Wellbutrin 150 mg if you have:
- History of seizures
- Eating disorders
- Diabetes
- High Blood Pressure
- Bipolar disorder (manic depression) or psychosis
- Concurrent use of MAOIs (Monoamine Oxidase Inhibitors) or certain medications
How well does Wellbutrin work as compared to other antidepressants?
Wellbutrin 150mg works differently compared to many other antidepressants. It is not an SSRI (Selective Serotonin reuptake inhibitor) like drugs Prozac or Zoloft. Instead wellbutrin 150mg is a norepinephrine-dopamine reuptake inhibitor (NDRI).
The choice between Wellbutrin 150mg and other antidepressants depends upon the patient’s specific needs and the nature of the depression. Wellbutrin 150mg is known for having a unique profile with potential benefits such as reduced risk of weight or sexual side effects, while SSRIs can lead to a range of prolonged side effects like weight gain, sleeplessness, and sexual dysfunctions.
Conclusion
In this article we have discussed does wellbutrin 150mg works, and the factors affecting its effectiveness. We have also discussed its common side effects and compared it with other antidepressants like SSRIs. Upon discussion, it becomes evident that Wellbutrin 150mg may be more suitable for patients with major symptoms of depression.
Was this helpful?
References
1.-
Acheson A, de Wit H. Bupropion improves attention but does not affect impulsive behavior in healthy young adults. Experimental and clinical psychopharmacology. 2008 Apr;16(2):113. Available from: https://psycnet.apa.org/record/2008-03846-002
2.-
Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs. 2008 Apr;68:653-89. Available from: https://link.springer.com/article/10.2165/00003495-200868050-00011
3.-
Predictable SE, Laurencic G, Malone D. Side effects of antidepressants: an overview. Cleveland Clin J Med. 2006 Apr;73(4):351.Available from: https://down.documentine.com/7798db166f7343656e61b398bbd09cdd.pdf
Find a supportive therapist who can help with Depression.
Discover the convenience of BetterHelp, an online therapy platform connecting you with licensed and accredited therapists specialized in addressing issues such as depression, anxiety, relationships, and more. Complete the assessment and find your ideal therapist within just 48 hours.
AskYourPharm is user-supported. We may earn a commission if you sign up for BetterHelp’s services after clicking through from this site
